[Combination therapy of insulin sensitizer, thiazolidinedione drugs, and sulfonylurea].
Ohmura
Eiji
E
Department of Medicine 1, Saitama Medical Center, Saitama Medical School.
Hosaka
Daiya
D
Imai
Yasuo
Y
Kawazu
Shoji
S
D001786:Blood Glucose / Q000378:metabolism; D002839:Chromans / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D004359:Drug Therapy, Combination; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance; D000077205:Pioglitazone; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*; D045162:Thiazolidinediones; D000077288:Troglitazone
D001786:Blood Glucose; D002839:Chromans; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000077205:Pioglitazone; D013453:Sulfonylurea Compounds; D013844:Thiazoles; D045162:Thiazolidinediones; D000077288:Troglitazone; C089946:2,4-thiazolidinedione